A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years

NCT05345873 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
SARS-CoV-2 Infection

Interventions

BIOLOGICAL: SCTV01E
BIOLOGICAL: mRNA-1273

Sponsor

Sinocelltech Ltd.